Mode
Text Size
Log in / Sign up
Phase 3 N=44 Randomized Treatment

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Overweight · Obese

Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Nov 2016
Primary outcome: Primary: Change in Waist Circumference — -2.3; -6.0; -4.0 cm — p=0.398

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
LLLT (Device); Lorcaserin (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Mayo Clinic
Primary completion
Dec 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Waist Circumference
-2.3; -6.0; -4.0 0.398
PRIMARY
Change in Weight
-1.0; -3.7; -3.5 0.070

Summary

Currently in the United States about 97 million adults are considered obese, accounting for about 33% of the American adult population (compared to 22.9% in 1988). Obesity, defined as a body mass index of 30.0 or higher, is accountable for 44% of the diabetes, 23% of the ischemic heart disease and between 7% and 41% of certain cancers. The Erchonia® Zerona™ 2.0 Laser (which will be used in this study) has been approved by the FDA (K123237) as a non-invasive dermatological aesthetic treatment which can be used by individuals intending to reduce circumference of hips, waist, and thighs. Lorcaserin is a selective serotonin 2C (5-HT(2C)) receptor agonist. The exact mechanism of action is not known, but lorcaserin is believed to promote satiety and decrease food intake by activating 5-HT(2C) receptors on anorexigenic pro-opiomelanocortin neurons in the hypothalamus. Lorcaserin was approved by the FDA on June 2012 for weight management in people with a BMI of > 27 kg/m2 (overweight) when accompanied by a weigh-related condition such as type 2 diabetes or high blood pressure or in people with a BMI > 30 kg/m2 (obese). The purpose of this pilot study is to obtain preliminary data on: 1) effectiveness of the combination of LLLT and lorcaserin for reducing abdominal subcutaneous fat in overweight/obese individuals; 2) impact of LLLT on inflammatory biomarkers, blood sugar, and cholesterol.

Eligibility Criteria

Inclusion Criteria

  • be 18-70 years of age;
  • have a body weight of greater than 50 kg (110 pounds);
  • have a BMI 27-39.9 kg/m2;
  • be weight concerned;
  • be motivated to reduce their central adiposity;
  • be able to participate fully in all aspects of the study;
  • have understood and signed study informed consent.

Exclusion Criteria

  • have used weight loss medications or participated in a weight loss program within the past 30 days;
  • are currently taking supplements known to affect weight, such as garcinia cambrogia.
  • have had weight fluctuations of 20 pounds or more in the past 6 months (self-report);
  • have an implanted device (including pacemaker or lap band) in the targeted area of LLLT;
  • have an active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression);
  • have used an investigational drug within 30 days of study enrollment;
  • have a recent history (past 30 days) of alcohol or drug abuse or dependence;
  • are currently pregnant or lactating, or are of child-bearing potential or are likely to become pregnant during the medication phase and are unwilling to use a reliable form of contraception;
  • have a history of any major cardiovascular events including heart valve disease, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease;
  • have current uncontrolled hypertension (systolic > 165 mm Hg or diastolic > 95 mm Hg) documented on 2 separate occasions;
  • have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as diabetes) or active cancer or are within 1 year of cancer remission;
  • Prior surgical intervention for body sculpting/weight loss, such as liposuction, abdominoplasty, stomach stapling, lap band surgery, etc.;
  • medical, physical, or other contraindications for body sculpting/weight loss;
  • current use of medication(s) known to affect weight levels/cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent;
  • concurrently taking a serotonergic drug (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), triptans, bupropion, dextromethorphan, St. John's Wort). These drugs can be used to treat depression and/or migraines but are contraindicated with lorcaserin;
  • any medical condition known to affect weight levels and/or to cause bloating or swelling;
  • diagnosis of, and/or taking medication for, irritable bowel syndrome;
  • active infection, wound or other external trauma to the areas to be treated with the laser;
  • known photosensitivity disorder;
  • are allergic to lorcaserin;
  • current active cancer or currently receiving treatment for cancer; or
  • have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence;
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02129608). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search